Phase 3
Completed N=250
Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
Dengue Fever · Dengue Hemorrhagic Fever
Source: ClinicalTrials.gov NCT01254422 ↗
Enrolled (actual)
250
Serious AEs
7.2%
Results posted
Jul 2019
Primary outcomePrimary: Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Vaccination With Either CYD Dengue Vaccine or a Placebo — 69.3; 56.9; 1.0; 0.0 Percentage of participants
◆ Published Evidence
Established
49citations · ~4 / year
Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
Summary
The purpose of this study was to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia.
Primary Objectives:
* To describe the safety (in terms of solicited and unsolicited adverse events) of the CYD dengue vaccine in all participants after each injection.
* To describe the antibody response to each dengue virus serotype post-injection 2 and post-injection 3.
Linked Publications
-
Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Vaccination With Either CYD Dengue Vaccine or a Placebo |
69.3; 56.9; 1.0; 0.0; 46.7; 49.0 | — |
| PRIMARY Percentage of Flavivirus-Immune Participants Reporting Solicited Injection Site and Systemic Reactions Following Each Vaccination With CYD Dengue Vaccine or Placebo Vaccine |
44.5; 29.0; 14.5; 29.0; 13.6; 22.6 | — |
| PRIMARY Percentage of Flavivirus-Naïve Participants Reporting Solicited Injection-site and Systemic Reactions Following Each Vaccination With CYD Dengue Vaccine or a Placebo Vaccine |
37.5; 25.0; 31.8; 15.0; 25.0; 20.0 | — |
| PRIMARY Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo |
31.1; 32.0; 90.3; 34.0; 96.4; 30.0 | — |
| PRIMARY Percentage of Participants With Seropositivity Against at Least One, Two, Three, or the Four Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo |
44.9; 48.0; 100.0; 46.0; 100.0; 42.0 | — |
| PRIMARY Geometric Mean Titers (GMTs) Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo |
15.3; 18.6; 119; 21.0; 151; 18.9 | — |
| PRIMARY Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo: Flavivirus-Immune Participants |
56.0; 51.6; 96.3; 48.4; 97.2; 41.9 | — |
| PRIMARY Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo: Flavivirus-Naive Participants |
0.0; 0.0; 82.8; 10.5; 95.4; 10.5 | — |
| PRIMARY GMTs of Flavivirus-Immune Participants Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo |
37.5; 41.7; 248; 45.4; 247; 33.5 | — |
| PRIMARY GMT of Flavivirus-Naïve Participants Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo |
5.00; 5.00; 47.1; 5.98; 81.6; 7.38 | — |
Eligibility Criteria
Inclusion Criteria
- Aged 2 to 11 years on the day of inclusion
- Assent form was signed and dated by the participant (for participants ≥ 7 years) and informed consent form was signed and dated by the parent(s) or another legally accepted representative, and by an independent witness if the two parents or legally accepted representative were illiterate
- Participant and parent/legally accepted representative were able to attend all scheduled visits to comply with all trial procedures
- Participants in good health, based on medical history and physical examination
- For a female participant of childbearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior to the first vaccination, until at least 4 weeks after the last vaccination
Exclusion Criteria
- Known pregnancy, or a positive urine pregnancy test (for female participant of child-bearing potential only)
- Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
- Planned participation in another clinical trial during the present trial period
- Planned receipt of any vaccine in the 4 weeks following the trial first vaccination, except for pandemic influenza vaccination
- Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Seropositivity for human immunodeficiency virus (HIV) reported by the parent/legally acceptable representative
- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
- Chronic illness that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion
- Participants who plan to move to another country/region within the 18 coming months
- Identified as a child (adopted or natural) of the Investigator or of site employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center.
Data sourced from ClinicalTrials.gov (NCT01254422) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.